When PD-L1 positivity on cancer or inflammatory cells is considered, of the 177 TNBC evaluable, 163 (92.1%) were PD-L1+ with no significant difference in frequency between BRCA1-associated and sporadic TNBC (P=0.11: Table 2). This evidence concerns the gene BRCA1 and cancer.